Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery

References

• Hait WN, Lebowitz PF. Moving upstream in anticancer drug development. Nat Rev. 2019;18(3):159–160. doi:10.1038/d41573-018-00006-3
   Google Scholar
• Coty J-B, Vauthier C. Characterization of nanomedicines: a reflection on a field under construction needed for clinical translation success. J Control Release. 2019;275(10):254–268. doi:10.1016/j.jconrel.2018.02.013
   Google Scholar
• Aleksandrowicz R, Taciak B, Krol M. Drug delivery systems improving chemical and physical properties of anticancer drugs. J Physiol Pharmacol. 2017;68(2):165–174.28614765
   PubMed Web of Science ®Google Scholar
• Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38. doi:10.1016/j.addr.2016.04.02527137110
   PubMed Web of Science ®Google Scholar
• Moro M, Di Paolo D, Milione M, et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J Control Release. 2019;308:44–56. doi:10.1016/j.jconrel.2019.07.00631299263
   PubMed Web of Science ®Google Scholar
• Crecente-Campo J, Guerra-Varela J, Peleteiro M, et al. The size and composition of polymeric nanocapsules dictate their interaction with macrophages and biodistribution in zebrafish. J Control Release. 2019;308:98–108. doi:10.1016/j.jconrel.2019.07.01131306677
   PubMed Web of Science ®Google Scholar
• Zhou Q, Li Y, Zhu Y, et al. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. J Control Release. 2018;275:67–77. doi:10.1016/j.jconrel.2018.02.02629471038
   PubMedGoogle Scholar
• Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G, Ruozi B. Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin. Expert Opin Drug Deliv. 2017;14(7):825–840. doi:10.1080/17425247.2017.124352827690258
   PubMed Web of Science ®Google Scholar
• Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010;99(6):2557–2575. doi:10.1002/jps.2205420049941
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Lim S. Engineering protein nanocages as carriers for biomedical applications. NPG Asia Mater. 2017;9:e371(1–18). doi:10.1038/am.2016.128
   PubMed Web of Science ®Google Scholar
• Tosi G, Belletti D, Pederzoli F, Ruozi B. Apoferritin nanocage as drug reservoir: is it a reliable drug delivery system? Expert Opin Drug Deliv. 2016;13(10):1341–1343. doi:10.1080/17425247.2016.122484827560784
   PubMed Web of Science ®Google Scholar
• Truffi M, Fiandra L, Sorrentino L, Monieri M, Corsi F, Mazzucchelli S. Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res. 2016;107:57–65. doi:10.1016/j.phrs.2016.03.00226968122
   PubMed Web of Science ®Google Scholar
• Al-Ani AW, Zhang L, Ferreira L, Turyanska L, Bradshaw TD, Thomas NR. Listeria innocua Dps as a nanoplatform for bioluminescence based photodynamic therapy utilizing gaussia princeps luciferase and zinc protoporphyrin IX. Nanomedicine: NBM. 2019;20:102005(1–10).
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291–317. doi:10.1016/j.bbagen.2011.07.01621851850
   PubMed Web of Science ®Google Scholar
• Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8(6):916–931.30034931
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Can. 2001;37(4):9–15. doi:10.1016/S0959-8049(01)00231-3
   PubMedGoogle Scholar
• Bradshaw TD, Wrigley S, Shi D-F, Schultz RJ, Paull KD, Stevens MFG. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro and in vivo activity. Br J Cancer. 1998;77(5):745–752. doi:10.1038/bjc.1998.1229514053
   PubMed Web of Science ®Google Scholar
• Tan BS, Tiong KH, Muruhadas A, et al. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610; NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther. 2011;10(10):1982–1992. doi:10.1158/1535-7163.MCT-11-039121831963
   PubMed Web of Science ®Google Scholar
• Stone EL, Citossi F, Singh R, et al. Antitumour benzothiazoles 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F 203 hydrogels for local delivery. Bioorg Med Chem. 2015;23(21):6891–6899. doi:10.1016/j.bmc.2015.09.05226474663
   PubMedGoogle Scholar
• Bradshaw TD, Wren JE, Bruce M, et al. Preclinical toxicokinetic evaluation of phortress (2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride) in two rodent species. Pharmacology. 2009;83(2):99–109. doi:10.1159/00018384619088497
   PubMed Web of Science ®Google Scholar
• Hennequin B, Turyanska L, Ben T, et al. Aqueous near‐infrared fluorescent composites based on apoferritin‐encapsulated PbS quantum dots. Adv Mater. 2008;20(19):3592–3596. doi:10.1002/adma.v20:19
   Web of Science ®Google Scholar
• Bradshaw TD, Junor M, Patane A, et al. Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells. J Mat Chem B. 2013;1(45):6254–6260. doi:10.1039/c3tb21197e
   PubMed Web of Science ®Google Scholar
• Liang M, Fan K, Zhou M, et al. H-ferritin–nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc Natl Acad Sci USA. 2014;111(41):14900–14905. doi:10.1073/pnas.140780811125267615
   PubMed Web of Science ®Google Scholar
• Wang Z, Gao H, Zhang Y, Liu G, Niu G, Chen X. Functional ferritin nanoparticles for biomedical applications. Front Chem Sci Eng. 2017;11(4):633–646. doi:10.1007/s11705-017-1620-829503759
   PubMedGoogle Scholar
• Breen A, Wells G, Turyanska L, Bradshaw TD. Development of novel apoferritin formulations for antitumour benzothiazoles. Cancer Rep. 2019;e1155(1–7). doi:10.1002/cnr2.1155
   Google Scholar
• Bradshaw TD, Fichtner I, Bibby MJ, et al. Preclinical evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Can Ther. 2002;1:239–246.
   PubMed Web of Science ®Google Scholar
• Feng L, Dong Z, Tao D, Zhang Y, Liu Z. The acidic microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev. 2018;5:269–286. doi:10.1093/nsr/nwx062
   Web of Science ®Google Scholar
• Li L, Fang CJ, Ryan JC, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci USA. 2010;107(8):3505–3510. doi:10.1073/pnas.091319210720133674
   PubMed Web of Science ®Google Scholar
• Kashiyama E, Hutchinson I, Chua M-S, et al. Antitumor benzothiazoles. 8.1 synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)-benzothiazoles3. J Med Chem. 1999;42(20):4172–4184.10514287
   PubMed Web of Science ®Google Scholar
• Bradshaw TD, Chua M-S, Browne HL, Trapani V, Sausville EA, Stevens MFG. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer. 2001;86(8):1348–1354.
   Web of Science ®Google Scholar
• Hose CD, Hollingshead M, Sausville EA, Monks A. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther. 2003;2(12):1265–1272.14707267
   PubMed Web of Science ®Google Scholar
• Bazzi R, Rowlands C, Bradshaw TD, Stevens MFG, Bell D. 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor. Toxico. Appl Pharmaco. 2009;237(1):102–110. doi:10.1016/j.taap.2009.02.015
   PubMed Web of Science ®Google Scholar
• Hutchinson I, Chua M-S, Browne HL, et al. The synthesis and in vitro biological activity of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem. 2001;44(9):1446–1455. doi:10.1021/jm001104n11311068
   PubMed Web of Science ®Google Scholar
• Shi D-F, Bradshaw TD, Wrigley S, et al. Antitumor benzothiazoles 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem. 1996;39(17):3375–3384. doi:10.1021/jm96009598765521
   PubMed Web of Science ®Google Scholar
• Bradshaw TD, Chua M-S, Browne HL, Trapani V, Sausville EA, Stevens MFG. In vitro evaluation of amino acid prodrugs of novel 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer. 2002;86(8):1348–1354. doi:10.1038/sj.bjc.660022511953897
   PubMed Web of Science ®Google Scholar
• Bradshaw TD, Shi D-F, Schultz RJ, et al. Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cell lines in vitro and in vivo. Br J Cancer. 1998;78(4):421–429. doi:10.1038/bjc.1998.5109716022
   PubMedGoogle Scholar
• Callero MA, Luzzani GA, De Dios DO, Bradshaw TD, Loaiza-Perez AI. Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) in ovarian cancer. J Cell Biochem. 2013;114(10):2392–2404. doi:10.1002/jcb.2458923696052
   PubMedGoogle Scholar
• Andersson P, McGuire J, Rubio C, et al. A constitutively active dioxin/aryl hydrocarbon receptor induced stomach tumors. Proc Natl Acad Sci USA. 2002;99(15):9990–9995. doi:10.1073/pnas.15270629912107286
   PubMed Web of Science ®Google Scholar
• Peng TL, Chen J, Mao W, Song X, Chen M-H. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol. 2009;10:27. doi:10.1186/1471-2121-10-2719371443
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wan D, Yang J, Hammock BD, Ortiz de Montallano P. Catalytic activities of tumour-specific human cytochrome P450 CYP2W1 towards endogenous substrates. DMD. 2016;44(5):771–780. doi:10.1124/dmd.116.069633
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Tang T, et al. The antitumor activity of 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) in human gastric cancer models is mediated by arylhydrocarbon receptor (AhR) signalling. J Cellulat and Molecular Medicine In press 2019.
   Google Scholar